



Markets
/
Stocks
/
nasdaq-alny
/

Alnylam Pharmaceuticals Inc

ALNY

View Detailed Chart

263.240USD

+6.050+2.35%

Close 04/30, 16:00（ET）Quotes delayed by 15 min

34.04BMarket Cap

LossP/E TTM



Alnylam Pharmaceuticals Inc

263.240

+6.050+2.35%

Company

Intraday

30m

Today

+2.35%

5 Days

+8.79%

1 Month

+8.58%

6 Months

-6.48%

Year to Date

+11.87%

1 Year

+82.87%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 33 analysts

BUY

Current Rating

318.429

Target Price

23.81%

Rising Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

162

Total

Median

Average

Company name

Ratings

Analysts

Alnylam Pharmaceuticals Inc

ALNY

Biogen Inc

BIIB

Vertex Pharmaceuticals Inc

VRTX

Amgen Inc

AMGN

Gilead Sciences Inc

GILD

BioMarin Pharmaceutical Inc

BMRN

...

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Buy

Sell(1)

Neutral(2)

Buy(7)

Indicators

Sell(1)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

7.223

Neutral

RSI(14)

61.537

Neutral

STOCH(KDJ)(9,3,3)

94.447

Overbought

ATR(14)

10.927

Low Volatility

CCI(14)

147.377

Buy

Williams %R

0.899

Overbought

TRIX(12,20)

-0.012

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

253.890

Buy

MA10

244.598

Buy

MA20

242.312

Buy

MA50

250.473

Buy

MA100

249.842

Buy

MA200

257.850

Buy

News

More news coming soon, stay tuned...

Company

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Company codeALNY

CompanyAlnylam Pharmaceuticals Inc

CEODr. Yvonne L. Greenstreet, M.D.

Websitehttps://www.alnylam.com/